Double‐blind placebo‐controlled trial of the effect of omalizumab on basophils in chronic urticaria patients
Clinical & Experimental Allergy2017Vol. 48(2), pp. 196–204
Citations Over TimeTop 10% of 2017 papers
Lukas Jörg, Tatjana Pecaric-Petkovic, Stephan Reichenbach, Michael Coslovsky, Odile Stalder, Werner J. Pichler, Oliver Hausmann
Abstract
We demonstrated a rapid reduction of FcεRI receptor density on basophils following treatment with omalizumab. Because CU-BAT using well-characterized, omalizumab-naïve donor basophils did not change during the treatment phase, autoreactive serum factors seem to remain unaltered. This points towards a cellular effect of omalizumab on basophils. To predict the omalizumab response time and to monitor disease, FcεRI density and CU-BAT might be promising cellular-based assays.
Related Papers
- → IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms(2022)51 cited
- → Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children(2014)42 cited
- → Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria(2020)11 cited
- → Kinetic Profiling of Clinical Symptoms and Basophil Parameters During Treatment of Chronic Spontaneous Urticaria with Omalizumab(2019)2 cited
- → Faculty Opinions recommendation of The Efficacy of Omalizumab Treatment in Chronic Spontaneous Urticaria is Associated with Basophil Phenotypes.(2021)